	2012 Jun 30	C 2013 Jun 30	C 2014 Jun 30	2015 Jun 30	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	9M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	107	127	173	252	239	402	540	649	863	1,061	1,269	1,467	1,694	1,937	2,187
Cost of Operating Revenue	80	88	113	160	142	211	270	328	463	528	629	740	816	882	938
Gross Profit	27	39	60	92	97	191	270	321	400	533	641	727	878	1,056	1,249
Gross Margin	25.0	30.4	34.8	36.4	40.5	47.5	50.1	49.5	46.4	50.2	50.5	49.6	51.8	54.5	57.1
Total Operating Expenses	93	104	138	199	179	290	364	441	635	769	921	1,070	1,195	1,353	1,499
Operating Profit	15	23	35	53	59	112	176	208	228	292	348	397	499	585	688
Operating Margin	13.5	18.0	20.3	21.1	24.9	27.8	32.6	32.1	26.5	27.5	27.4	27.1	29.5	30.2	31.5
Financing Income/(Expense) - Net	-3	-1	-1	0	0	9	11	15	39	24	35	50	60	88	-1
Profit before Taxes	11	22	36	53	60	121	188	227	269	314	386	451	564	677	803
Income Taxes	3	8	10	12	14	25	44	50	54	62	77	74	103	136	153
Profit after Tax	8	14	26	41	46	96	145	177	215	242	300	376	457	536	641
PAT Margin	7.5	11.0	14.9	16.3	19.2	23.8	26.8	27.2	24.9	22.8	23.6	25.7	27.0	27.7	29.3
EPS - Basic - ex Extraordinary Items	1.06	1.85	3.42	5.43	6.06	12.65	19.16	23.35	28.42	32.03	39.61	49.62	60.19	70.57	84.36
EPS - Diluted - ex Extraordinary Items	1.06	1.85	3.42	5.43	6.06	12.65	19.16	23.23	28.42	31.74	39.26	49.18	59.90	70.25	84.11
EBIT	15	23	35	53	59	112	176	208	228	292	348	397	499	585	688
EBITDA	16	24	39	62	67	125	195	231	260	329	395	442	552	651	761
EBITDA Margin	14.7	19.2	22.4	24.5	28.0	31.1	36.1	35.7	30.1	31.0	31.1	30.1	32.6	33.6	34.8

Balance Sheet

Abridged

Understanding Balance Sheet

Caplin Point Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Jun 30	2013 Jun 30	2014 Jun 30	2015 Jun 30	C 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	54	39	49	82	118	179	304	494	823	1,036	1,298	1,554	1,893	2,134	2,586
Long-Term Investments	1	1	0	0	0	13	0	0	1	1	63	71	138	286	502
Property Plant & Equipment - Net	40	84	127	143	144	154	183	234	288	312	293	489	557	674	760
Total Non-Current Assets	53	96	131	147	149	179	196	249	303	328	439	637	805	1,074	1,460
Total Assets	107	135	180	229	267	358	500	743	1,126	1,364	1,736	2,191	2,698	3,208	4,045
Total Current Liabilities	69	83	108	125	118	113	109	86	144	143	208	268	331	306	386
Long Term Debt	2	3	2	1	1	0	0	0	1	1	1	1	1	3	2
Total Non-Current Liabilities	4	9	10	10	13	20	28	23	25	10	13	12	12	5	29
Total Liabilities	73	92	118	135	131	133	137	110	169	153	220	280	344	311	415
Total Shareholders' Equity	34	43	62	93	135	225	364	633	948	1,193	1,490	1,885	2,323	2,861	3,586
Minority Interest	0	0	0	0	0	0	0	0	9	18	26	27	31	36	44
Total Equity	34	43	62	93	136	225	364	633	957	1,210	1,516	1,912	2,354	2,897	3,631
Total Liabilities & Equity	107	135	180	229	267	358	500	743	1,126	1,364	1,736	2,191	2,698	3,208	4,045

Cash Flow

Abridged

Understanding Cash Flow Statement

Caplin Point Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Jun 30	2013 Jun 30	C 2014 Jun 30	2015 Jun 30	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	9M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	8.15	15.84	32.30	50.44	49.74	111.69	172.15	201.90	220.02	282.58	353.66	401.16	500.78	605.76	693.75
Working Capital - Increase/(Decrease)	18.89	15.81	29.32	2.00	-5.13	-38.39	-100.38	-120.06	-177.11	-4.80	1.99	-103.75	-139.44	-122.28	-108.99
Net CF from Operating Activities	27.03	31.66	61.62	52.44	44.61	73.30	71.78	81.84	42.91	277.78	355.65	297.41	361.34	483.48	584.76
Capital Expenditures - Net	16.45	45.40	46.55	25.44	8.05	25.03	48.52	65.18	76.74	70.48	91.18	193.47	145.82	191.52	248.13
Net CF from Investing Activities	-16.45	-45.45	-45.80	-25.45	-8.04	-41.93	-74.37	-98.93	-53.00	-18.91	-290.54	-244.40	-363.77	-386.45	-644.69
Dividends Paid - Cash - Total	-	-	4.42	7.25	13.64	6.37	11.34	15.12	32.53	3.03	22.69	30.32	34.17	37.99	45.61
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	0.01	0.01	105.01	113.00	-	-	0.02	0.01	0.01	-
Debt - LT & ST - Issuance/(Retirement) - Total	-2.79	-3.22	-1.42	-1.19	-0.20	-0.26	-0.21	-0.04	-0.22	-19.41	-16.56	2.91	-3.13	0.27	0.02
Net Cash Flow from Financing Activities	-0.40	-1.18	-5.83	-8.44	-13.84	-6.62	-11.54	89.85	80.04	-22.44	-40.01	-27.39	-37.29	-37.71	-45.59
Free Cash Flow to Equity	7.80	-16.96	13.65	25.81	36.36	48.02	23.05	16.62	-34.05	187.89	247.91	106.85	212.39	292.23	336.65
Free Operating CF net dividend	10.59	-13.74	10.65	19.70	22.72	41.36	11.92	1.53	-66.36	204.27	241.78	73.62	181.35	253.97	291.02
Free Operating CF	10.59	-13.74	15.07	26.96	36.36	47.73	23.26	16.66	-33.83	207.30	264.47	103.94	215.52	291.96	336.63

Business Segment Analysis

FY End:

Mar 25

Caplin Point Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals formulations (100.0%)₹ 191.52 Cr

Revenue / Sales

Pharmaceuticals formulations (100.0%)₹ 1,937.47 Cr

Assets

Pharmaceuticals formulations (100.0%)₹ 3,207.85 Cr

Operating Income

Pharmaceuticals formulations (100.0%)₹ 584.92 Cr

Regional Segment Analysis

FY End:

Mar 25

Caplin Point Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Rest of the world (77.8%)₹ 1,582.96 CrUSA (17.4%)₹ 354.51 CrUnallocated (4.7%)₹ 96.43 Cr

Assets

Rest of the world (45.1%)₹ 1,448.25 CrUnallocated (36.8%)₹ 1,179.51 CrUSA (18.1%)₹ 580.09 Cr

Historical Segment Analysis

Track how Caplin Point Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals formulations	77	70	91	193	146	192

Frequently Asked Questions

What is the revenue of Caplin Point Laboratories Ltd.?

The latest trailing twelve month revenue of Caplin Point Laboratories Ltd. is ₹ 2,187.19 Cr, reflecting a 1-year growth of 12.89% and a 3-year CAGR of 14.25%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Caplin Point Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Caplin Point Laboratories Ltd. is ₹ 641.24 Cr, with a 3-year earnings CAGR of 19.59%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Caplin Point Laboratories Ltd.?

The trailing twelve month EBITDA of Caplin Point Laboratories Ltd. is approximately ₹ 688.08 Cr (based on an operating margin of 31.46%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Caplin Point Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Caplin Point Laboratories Ltd. is 84.11. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Caplin Point Laboratories Ltd.?

The debt-to-equity ratio of Caplin Point Laboratories Ltd. stands at 0.00. The interest coverage ratio is 790.90x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Caplin Point Laboratories Ltd.?

The estimated book value per share of Caplin Point Laboratories Ltd. is 471.82 (derived from a P/B ratio of 5.54 and market price of ₹ 2,612.20), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Caplin Point Laboratories Ltd.?

The trailing twelve month operating cash flow of Caplin Point Laboratories Ltd. is ₹ 584.76 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Caplin Point Laboratories Ltd. report consolidated or standalone financials?

Caplin Point Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.